Date:6/22/2011

he creation of skilled manufacturing, packaging and quality control/quality assurance and other jobs that will create opportunities for the population of Salt Lake City and the surrounding areas.  We are delighted to have Governor Herbert join us in commemorating Watson's significant investment in the future of our Company and in the future of the Salt Lake City community."

Watson's Salt Lake City facility is the headquarters for the Company's Global Brands research and development operations, with approximately 175 professionals involved in product development.  In addition, the Salt Lake City facility manufactures and packages brand and generic transdermal patch and topical gel pharmaceutical products, and currently employs more than 200 people in manufacturing and operations.  

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is a leading integrated global specialty pharmaceutical company.  The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health.  Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking StatementStatements contained in this press release that refer to Watson's estimated or anticipated financial results or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. For instance, any statements in this press release concerning prospects related to Watson's product development activities, product introductions, product launch timing, and anticipated financial performance are forward-looking statements. It is important to note that Watson's goals and expectatio
'/>"/>

SOURCE Watson Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Watson to Present at 2011 Wells Fargo Securities Healthcare Conference
2. Watson Confirms AVODART(R) Patent Challenge
3. Watson Confirms Court Decision Rejecting Tevas Motion to Prevent Launch of Generic SEASONIQUE®
4. Watsons Nabumetone Tablets Receive FDA Approval
5. Watson Confirms Pataday™ Patent Challenge
6. Watson Confirms Viagra® Patent Challenge
7. Watson to Present at the Goldman Sachs 32nd Annual Global Healthcare Conference
8. Watson Launches Generic AMRIX®
9. Watson Launches Generic Concerta®
10. Watson Pharmaceuticals to Webcast Annual Meeting of Stockholders on May 13th
11. Watson First Quarter 2011 Net Revenue Increases to $877 Million